Tag: AJICAP
AJICAP Second-generation: Realizing Versatility and Robustness through Fc-Affinity Guided Chemical Conjugation...
Over the past decade, site-specific chemical conjugation has emerged as a promising strategy to produce antibody-drug conjugates (ADCs) in the field of oncology [1]. Daiichi-Sankyo's chemical conjugation method, which uses high drug-to-antibody ratio (DAR) technology, was approved by the U.S. Food and Drug Administration as the first site-specific ADC (fam-trastuzumab-deruxtecan-nxki; Enhertu® | Daiichi Sankyo and AstraZeneca).
Ajinomoto and Exelixis to Jointly Develop Novel Antibody-drug Conjugates
Ajinomoto and Exelixis have signed a license agreement with to incorporate AJICAP®, Ajinomoto's proprietary site-specific bioconjugation and linker technologies, in the development of novel antibody-drug conjugate (ADC) programs being developed by Exelixis.
Trio Pharmaceuticals and Ajinomoto Ink Agreement to Develop First-in-class Dual Functionality...
Patients being treated for cancer may often benefit from a combination of systemic cancer chemotherapies. The rationale for the combination of multiple anti-cancer therapies...
New Bioconjugation Technology may help Better Control the Location of Payload...
A novel, proprietary site-selective bioconjugation technology, called AJICAP™ allows developers of therapeutic Antibody-drug Conjugates (ADCs) to better control both the location of payload conjugation...
